Relay Therapeutics (RLAY) Price/OCF Ratio: History & Chart

Relay Therapeutics, Inc.(RLAY)

Biotechnology · Cambridge, MA

$18.74-0.65 (-3.35%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.

Cambridge, MA

202 employees

www.relaytx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sanjiv K. Patel

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Relay Therapeutics, Inc. (RLAY)	$4.11B	N/A	N/A	N/A	N/A
LivaNova PLC (LIVN)vs ›	$4.12B	16.51	15.36	25.92	31.19
AbCellera Biologics Inc. (ABCL)vs ›	$4.02B	N/A	94.85	72.28	103.02
ICU Medical, Inc. (ICUI)vs ›	$3.99B	16.89	20.57	20.81	33.97
Adaptive Biotechnologies Corporation (ADPT)vs ›	$4.31B	N/A	17.21	17.21	17.21
Edgewise Therapeutics, Inc. (EWTX)vs ›	$4.31B	N/A	N/A	N/A	N/A
Heartflow, Inc. Common Stock (HTFL)vs ›	$4.37B	N/A	N/A	N/A	N/A
Indivior Pharmaceuticals Inc (INDV)vs ›	$4.48B	N/A	17.89	33.70	30.73
Regencell Bioscience Holdings Limited (RGC)vs ›	$3.64B	N/A	N/A	N/A	N/A
BillionToOne, Inc. (BLLN)vs ›	$4.60B	101.35	302.47	302.47	302.47

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Relay Therapeutics, Inc. (RLAY)

$4.11B

N/A

LivaNova PLC (LIVN)vs ›

$4.12B

16.51

15.36

25.92

31.19

AbCellera Biologics Inc. (ABCL)vs ›

$4.02B

N/A

94.85

72.28

103.02

ICU Medical, Inc. (ICUI)vs ›

$3.99B

16.89

20.57

20.81

33.97

Adaptive Biotechnologies Corporation (ADPT)vs ›

$4.31B

N/A

17.21

Edgewise Therapeutics, Inc. (EWTX)vs ›

$4.31B

N/A

Heartflow, Inc. Common Stock (HTFL)vs ›

$4.37B

N/A

Indivior Pharmaceuticals Inc (INDV)vs ›

$4.48B

N/A

17.89

33.70

30.73

Regencell Bioscience Holdings Limited (RGC)vs ›

$3.64B

N/A

BillionToOne, Inc. (BLLN)vs ›

$4.60B

101.35

302.47

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

RLAY Price/OCF Ratio Metrics

RLAY Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics